Quantcast
Last updated on April 24, 2014 at 10:21 EDT

Latest Thin film drug delivery Stories

2009-04-09 07:11:00

WARREN, N.J., April 9 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced the submission on April 7, 2009 of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the orally dissolving film strip (ODFS) formulation of ondansetron....

2009-04-09 07:00:00

Files NDA for Ondansetron Orally Dissolving Film Strip BioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF LAKE, N.J., April 9 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today provides an update on two of its pipeline products. Ondansetron Orally Dissolving Film Strip On April 7, 2009, Strativa submitted a New Drug Application (NDA) for its new orally dissolving film...

2009-04-02 14:44:00

TULSA, Okla., April 2 /PRNewswire/ -- enlyten is pleased to announce the signing of four time World Champion and 15 time NBA All Star Shaquille O'Neal as the official enlyten spokesperson. To view the multimedia assets associated with this release, please click http://news.prnewswire.com/viewrelease.aspx?STORY=MTQ= "Shaquille is a tremendous representative of the enlyten brand. He is indisputably one of the most extraordinary athletes in the world. His dominant play on the court coupled...

2009-04-02 07:33:00

Patent Addresses Use of Thin Film to Deliver Drugs and Vitamins via Pacifier or Porous Nipple WARREN, N.J., April 2 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that it has been granted U.S. Patent No. 7,500,984 from the United States Patent and Trademark Office (USPTO). The patent relates to the delivery of an active ingredient, such as drugs and/or vitamins,...

2009-03-12 15:02:00

Outlines 2008/Early 2009 Achievements WARREN, N.J. and PORTAGE, Ind., March 12 /PRNewswire/ - MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today it has received an additional $2.5 million in private debt financing from White Oak Global Advisors. The financing was triggered by the Company's achievement of certain milestones outlined in the $12.5 million private Loan and Security...

2009-03-12 13:53:00

WARREN, N.J., March 12 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that A. Mark Schobel, president and CEO, and Keith J. Kendall, executive vice president and CFO, are scheduled to present at the Cowen & Company 29th Annual Health Care Conference to be held on March 16 - 19 at the Boston Marriott Copley Place in Boston. Mr. Schobel and Mr. Kendall will also...

2008-12-16 08:07:00

WARREN, N.J. and PORTAGE, Ind., Dec. 16 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today that the Company has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical PLC ("Hikma") (LSE: HIK) (DIFX: HIK), a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of generic and in-licensed...

2008-12-02 07:00:00

On Track to File NDA with FDA in Early to Mid-2009 WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its development partner, MonoSol Rx, reported the successful completion of all pivotal bioequivalence studies for a thin film formulation of ondansetron. The ondansetron thin film product is being developed for the prevention of chemotherapy-induced nausea...

2008-12-02 07:00:00

Expects to File NDA with FDA in Early to Mid-2009 WARREN, N.J., Dec. 2 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced the successful completion of all pivotal bioequivalence studies for a thin film formulation of ondansetron. The ondansetron thin film...

2008-11-12 15:00:26

SOUTH BRUNSWICK, N.J., Nov. 12 /PRNewswire/ -- Tris Pharma, a privately owned, specialty pharmaceutical company, today unveiled a key component in the nation's fight against opioid abuse. Its new drug delivery platform, NoBuse(TM), offers a technology by which companies can deliver effective pain relief or ADHD products that are nearly impervious to abuse. In the United States, narcotic pain relievers have fueled a dangerous epidemic. One in five teens has abused a prescription pain...